Published in Am J Physiol Heart Circ Physiol on September 30, 2005
The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis (2007) 1.94
Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery. Ther Deliv (2011) 1.57
Bacterial endophthalmitis: therapeutic challenges and host-pathogen interactions. Prog Retin Eye Res (2007) 1.49
Transforming growth factor-beta signaling alters substrate permeability and tight junction protein expression at the blood-brain barrier during inflammatory pain. J Cereb Blood Flow Metab (2009) 1.22
The blood-brain barrier in neurodegenerative disease: a rhetorical perspective. J Neurochem (2009) 1.20
The impact of microglial activation on blood-brain barrier in brain diseases. Front Cell Neurosci (2014) 1.16
Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia. J Neurochem (2008) 1.07
Monocyte chemoattractant protein-1 in the choroid plexus: a potential link between vascular pro-inflammatory mediators and the CNS during peripheral tissue inflammation. Neuroscience (2008) 1.05
Inflammatory hyperalgesia induces essential bioactive lipid production in the spinal cord. J Neurochem (2010) 0.97
Biphasic cytoarchitecture and functional changes in the BBB induced by chronic inflammatory pain. Brain Res (2006) 0.90
Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des (2014) 0.88
Curcumin-loaded embryonic stem cell exosomes restored neurovascular unit following ischemia-reperfusion injury. Int J Biochem Cell Biol (2016) 0.85
Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain. Am J Physiol Heart Circ Physiol (2011) 0.83
Bacillus cereus induces permeability of an in vitro blood-retina barrier. Infect Immun (2008) 0.82
Administration of sesamol improved blood-brain barrier function in streptozotocin-induced diabetic rats. Exp Brain Res (2009) 0.81
The role of the blood-brain barrier in the development and treatment of migraine and other pain disorders. Front Cell Neurosci (2014) 0.81
Expression of the Nrf2-system at the blood-CSF barrier is modulated by neonatal inflammation and hypoxia-ischemia. J Inherit Metab Dis (2012) 0.81
Ghrelin prevents disruption of the blood-brain barrier after traumatic brain injury. J Neurotrauma (2011) 0.80
Cardio-metabolic risk factors and cortical thickness in a neurologically healthy male population: Results from the psychological, social and biological determinants of ill health (pSoBid) study. Neuroimage Clin (2013) 0.80
Age-associated physiological and pathological changes at the blood-brain barrier: A review. J Cereb Blood Flow Metab (2016) 0.80
Nonpharmacological Interventions in Targeting Pain-Related Brain Plasticity. Neural Plast (2017) 0.77
Adiponectin-Mediated Analgesia and Anti-Inflammatory Effects in Rat. PLoS One (2015) 0.77
Peptides at the blood brain barrier: Knowing me knowing you. Peptides (2015) 0.76
Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice. Malar J (2014) 0.76
Hypoxic Stress and Inflammatory Pain Disrupt Blood-Brain Barrier Tight Junctions: Implications for Drug Delivery to the Central Nervous System. AAPS J (2017) 0.75
Plasma Inflammatory Factors Are Associated with Anxiety, Depression, and Cognitive Problems in Adults with and without Methamphetamine Dependence: An Exploratory Protein Array Study. Front Psychiatry (2015) 0.75
Novel cytogenic and neurovascular niches due to blood-brain barrier compromise in the chronic pain brain. Mol Pain (2015) 0.75
Remodeling the blood-brain barrier microenvironment by natural products for brain tumor therapy. Acta Pharm Sin B (2017) 0.75
Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 27.85
IL-10 inhibits cytokine production by activated macrophages. J Immunol (1991) 13.13
Placebo-induced changes in FMRI in the anticipation and experience of pain. Science (2004) 8.33
Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science (2003) 5.58
Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol (2003) 2.57
Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke (2002) 2.50
Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol (1994) 1.77
Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol (1999) 1.68
Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J Pain (2005) 1.60
Dual role of the actin cytoskeleton in regulating cell adhesion mediated by the integrin lymphocyte function-associated molecule-1. Mol Biol Cell (1997) 1.54
Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol (2001) 1.54
Intercellular adhesion molecule-1 gene expression in human endothelial cells. Differential regulation by tumor necrosis factor-alpha and phorbol myristate acetate. J Biol Chem (1992) 1.53
Inflammatory mediators of cerebral endothelium: a role in ischemic brain inflammation. Brain Pathol (2000) 1.50
Intercellular adhesion molecule 1 activation induces tyrosine phosphorylation of the cytoskeleton-associated protein cortactin in brain microvessel endothelial cells. J Biol Chem (1994) 1.46
The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med (2002) 1.38
The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. Immunol Lett (2004) 1.37
Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol (2002) 1.35
Novel glucocorticoid effects on acute inflammation in the CNS. J Neurochem (2003) 1.33
HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem (2003) 1.31
HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol Cell Neurosci (2003) 1.29
Blood-brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain. Am J Physiol Heart Circ Physiol (2002) 1.20
Cyclooxygenase-2 modulates brain inflammation-related gene expression in central nervous system radiation injury. Brain Res Mol Brain Res (2002) 1.17
Immunopathogenesis of the multiple sclerosis lesion. Curr Neurol Neurosci Rep (2001) 1.16
Enhanced glial activation and expression of specific CNS inflammation-related molecules in aged versus young rats following cortical stab injury. J Neuroimmunol (2001) 1.15
Effect of systemic LPS injection on cortical NF-kappaB activity and inflammatory response following traumatic brain injury in rats. Brain Res (2004) 1.14
Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis. Brain (2003) 1.12
Microglial cells are a component of the perivascular glia limitans. J Neurosci Res (1991) 1.09
Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis (2004) 1.08
The role of inflammatory processes in the pathophysiology and treatment of brain and spinal cord trauma. Acta Neurochir Suppl (2004) 1.04
Crosstalk between components of the blood brain barrier and cells of the CNS in microglial activation in AIDS. Brain Pathol (2001) 1.02
Juxtavascular microglia migrate along brain microvessels following activation during early postnatal development. Glia (2002) 0.96
Polymorphisms of IL-1B, IL-1RN, IL-2, IL-4, IL-6, IL-10, and IFN-gamma genes in the Korean population. Hum Immunol (2003) 0.93
Rat microglial cells secrete predominantly the precursor of interleukin-1beta in response to lipopolysaccharide. Eur J Neurosci (2001) 0.92
Effect of lambda-carrageenan-induced inflammatory pain on brain uptake of codeine and antinociception. Brain Res (2004) 0.90
Increased ICAM-1 and VCAM-1 expression in the brains of autoimmune mice. J Neuroimmunol (2003) 0.90
Beta-amyloid peptide-induced blood-brain barrier disruption facilitates T-cell entry into the rat brain. Acta Histochem (2003) 0.89
Expression of P2X4 receptor by lesional activated microglia during formalin-induced inflammatory pain. J Neuroimmunol (2005) 0.89
Differential blood-brain barrier breakdown and leucocyte recruitment following excitotoxic lesions in juvenile and adult rats. Exp Neurol (1998) 0.88
Erythromycin exerts in vivo anti-inflammatory activity downregulating cell adhesion molecule expression. Br J Pharmacol (2005) 0.87
Measurement of mRNA for E-selectin, VCAM-1 and ICAM-1 by reverse transcription and the polymerase chain reaction. J Immunol Methods (1994) 0.86
Nitric oxide and prostaglandin E2 formation parallels blood-brain barrier disruption in an experimental rat model of bacterial meningitis. Brain Res Bull (1998) 0.86
Infiltration of inflammatory cells through brain endothelium. Pathol Biol (Paris) (1998) 0.83
Distribution of albumin nanoparticles in animals induced with the experimental allergic encephalomyelitis. J Drug Target (2000) 0.81
Thrombosis and altered expression of intercellular adhesion molecule-1 (ICAM-1) after avulsion injury in rat vessels. J Hand Surg Br (2004) 0.80
Adhesion molecule expression in experimental myositis. Muscle Nerve (2002) 0.77
Improvement of overexpression of endothelin B receptor in human cirrhotic liver by interferon therapy. J Gastroenterol (2003) 0.77
Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci (2001) 2.68
A prospective study of surgeon-performed ultrasound as the primary adjuvant modality for injured patient assessment. J Trauma (1995) 2.01
High specific activity labeling of protein with I-131 by the iodine monochloride method. Proc Soc Exp Biol Med (1966) 1.58
Doxycycline-induced esophageal ulceration in the U.S. Military service. Mil Med (2000) 1.56
Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol (2001) 1.54
Cuff failure in polyvinyl chloride tracheal tubes sprayed with lignocaine. Anaesthesia (1988) 1.42
Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc Natl Acad Sci U S A (1994) 1.32
Antinociceptive profile of biphalin, a dimeric enkephalin analog. J Pharmacol Exp Ther (1993) 1.30
Blood-brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain. Am J Physiol Heart Circ Physiol (2002) 1.20
A new tissue adhesive for laceration repair in children. J Pediatr (1998) 1.17
Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides (2001) 1.15
Distribution and analgesia of [3H][D-Pen2, D-Pen5]enkephalin and two halogenated analogs after intravenous administration. J Pharmacol Exp Ther (1991) 1.07
Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. J Pharmacol Exp Ther (2001) 1.03
Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine. J Pharmacol Exp Ther (1997) 1.02
Blood-to-central nervous system entry and stability of biphalin, a unique double-enkephalin analog, and its halogenated derivatives. J Pharmacol Exp Ther (1996) 1.01
Effects of cyclic flexion of coronary arteries on progression of atherosclerosis. Am J Cardiol (1994) 1.01
Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Res (2000) 1.00
Bioavailability and transport of peptides and peptide drugs into the brain. Peptides (1997) 1.00
Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. J Med Chem (2000) 1.00
Chronic inflammatory pain and the neurovascular unit: a central role for glia in maintaining BBB integrity? Curr Pharm Des (2008) 1.00
The effect of halogenation on blood-brain barrier permeability of a novel peptide drug. Peptides (1999) 0.99
Protein expression of brain endothelial cell E-cadherin after hypoxia/aglycemia: influence of astrocyte contact. Brain Res (1999) 0.98
Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun (1998) 0.98
Permeability of the blood-brain barrier to peptides: an approach to the development of therapeutically useful analogs. Peptides (1993) 0.96
Passage of a delta-opioid receptor selective enkephalin, [D-penicillamine2,5] enkephalin, across the blood-brain and the blood-cerebrospinal fluid barriers. J Neurochem (1996) 0.95
Assessment of an in vitro blood-brain barrier model using several [Met5]enkephalin opioid analogs. J Pharmacol Exp Ther (1993) 0.95
Combination of hypoxia/aglycemia compromises in vitro blood-brain barrier integrity. J Pharmacol Exp Ther (1999) 0.95
Cholesterol embolization: clinical findings and implications. J Am Coll Cardiol (1990) 0.93
Brain and spinal cord distribution of biphalin: correlation with opioid receptor density and mechanism of CNS entry. J Neurochem (1997) 0.91
Gangrene of the tongue caused by temporal arteritis. Med J Aust (1966) 0.90
Disposition of mitoxantrone in cancer patients. Cancer Res (1985) 0.90
Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion. Peptides (2000) 0.88
Regional distribution of putative vasopressin receptors in rat brain and pituitary by quantitative autoradiography. Proc Natl Acad Sci U S A (1984) 0.86
Neurotensin elevates cytosolic calcium in small cell lung cancer cells. Peptides (1990) 0.86
Fluorescence polarization immunoassay IV. Determination of phenytoin and phenobarbital in human serum and plasma. Clin Chem (1982) 0.86
Whole body and brain distribution of [3H]cyclic [D-Pen2,D-Pen5] enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration. J Pharmacol Exp Ther (1992) 0.86
Transport of opioid peptides into the central nervous system. J Pharm Sci (1998) 0.85
Doxepin effects on chronic pain, depression and plasma opioids. J Clin Psychiatry (1982) 0.85
Effect of peptidases at the blood brain barrier on the permeability of enkephalin. J Pharmacol Exp Ther (1994) 0.85
A model for hypokinesia: effects on muscle atrophy in the rat. J Appl Physiol Respir Environ Exerc Physiol (1980) 0.85
Ectoenzymes as sites of peptide regulation. Trends Pharmacol Sci (1996) 0.84
A hydrophobic interaction site for lysozyme binding to polyethylene glycol and model contact lens polymers. Biomaterials (1998) 0.83
Pharmacodynamic and pharmacokinetic characterization of poly(ethylene glycol) conjugation to met-enkephalin analog [D-Pen2, D-Pen5]-enkephalin (DPDPE). J Pharmacol Exp Ther (2001) 0.83
Aldosterone and ADH response to heat and dehydration in cattle. J Appl Physiol Respir Environ Exerc Physiol (1980) 0.83
Transport of the delta-opioid receptor agonist [D-penicillamine2,5] enkephalin across the blood-brain barrier involves transcytosis1. J Pharm Sci (1999) 0.82
Light microscopic autoradiographic visualization of [3H]-arginine vasopressin binding sites in rat brain. Life Sci (1983) 0.82
Volume and composition of hand sweat of White and Black men and women in desert walks. Am J Phys Anthropol (1983) 0.82
Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects. J Pharmacol Exp Ther (2013) 0.82
Clostridium welchii infection after amniocentesis. Br Med J (Clin Res Ed) (1984) 0.82
Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity. J Thromb Haemost (2013) 0.81
Enkephalin analog prodrugs: assessment of in vitro conversion, enzyme cleavage characterization and blood-brain barrier permeability. J Pharmacol Exp Ther (1996) 0.81
Protease inhibitors suppress in vitro growth of human small cell lung cancer. Peptides (1994) 0.81
Stabilization of ascorbic acid in human plasma, and its liquid-chromatographic measurement. Clin Chem (1988) 0.81
Stroke: development, prevention and treatment with peptidase inhibitors. Peptides (2000) 0.81
The entry of [D-penicillamine2,5]enkephalin into the central nervous system: saturation kinetics and specificity. J Pharmacol Exp Ther (1997) 0.81
Motility effects of opioid peptides in dog intestine. Life Sci (1983) 0.81
Structure-activity relationships of a series of [D-Ala2]deltorphin I and II analogues; in vitro blood-brain barrier permeability and stability. J Pharmacol Exp Ther (1997) 0.80
In vitro stability of some reduced peptide bond pseudopeptide analogues of dynorphin A. Peptides (1995) 0.80
Doxepin's effects on chronic pain and depression: a controlled study. J Clin Psychiatry (1984) 0.80
Effect of reduced flow on blood-brain barrier transport systems. Brain Res (2001) 0.80
Prohormone convertase and autocrine growth factor mRNAs are coexpressed in small cell lung carcinoma. J Mol Endocrinol (2000) 0.79
Quantitative analysis of prostaglandins in cell culture medium by high-resolution gas chromatography with electron-capture detection. J Chromatogr (1984) 0.79
Disposition of mitoxantrone in patients. Cancer Treat Rev (1983) 0.79
Assessment of stereoselectivity of trimethylphenylalanine analogues of delta-opioid [D-Pen(2),D-Pen(5)]-enkephalin. J Neurochem (2000) 0.79
Modifications of the 4,4'-residues and SAR studies of Biphalin, a highly potent opioid receptor active peptide. Bioorg Med Chem Lett (1998) 0.79
Endorphins and the central inhibition of urinary bladder motility. Peptides (1984) 0.79
[L-Ala3]DPDPE: a new enkephalin analog with a unique opioid receptor activity profile. Further evidence of delta-opioid receptor multiplicity. J Med Chem (1994) 0.79
Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone. J Chromatogr (1982) 0.79
Exploring why young African American women do not change condom-use behavior following participation in an STI/HIV prevention intervention. Health Educ Res (2012) 0.79
Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect. J Pharmacol Exp Ther (2000) 0.78
Effects of indomethacin and meclofenamate on renin release and renal hemodynamic function during chronic sodium depletion in conscious dogs. Circ Res (1980) 0.78
Isolation and characterization of in vitro central beta-endorphin metabolism in schizophrenia. Proc West Pharmacol Soc (1983) 0.78
Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. Cancer Res (1982) 0.78
Differential in vitro metabolism of beta-endorphin in schizophrenia. Peptides (1985) 0.78
Differential modulation of prohormone convertase mRNA by second messenger activators in two cholecystokinin-producing cell lines. Peptides (1996) 0.78
SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides (2001) 0.78
Time-dependent sensitization of plasma beta-endorphin in community elderly with self-reported environmental chemical odor intolerance. Biol Psychiatry (1996) 0.78
Urinary polyamines as markers of cardiac allograft rejection. A clinical evaluation. J Thorac Cardiovasc Surg (1988) 0.78
Alterations of peptide metabolism and neuropeptidase activity in senile dementia of the Alzheimer's type. Ann N Y Acad Sci (1997) 0.77
The role of serum and tissue pharmacology studies in the design and interpretation of chemoprevention trials. Prev Med (1989) 0.77
Distribution and pharmacokinetics of a potent peptide antagonist of parathyroid hormone and parathyroid hormone-related protein in the rat. J Pharmacol Exp Ther (1995) 0.77
Neurotensin is metabolized by endogenous proteases in prostate cancer cell lines. Peptides (1998) 0.77
Centrally acting drugs alter in vitro beta-endorphin processing in the rat. Eur J Pharmacol (1984) 0.77
Regional differences in gastrointestinal processing and absorption of epidermal growth factor in suckling rats. Am J Physiol (1991) 0.77
A non-equilibrium 24-hour vasopressin radioimmunoassay: development and basal levels in the rat brain. Brain Res (1983) 0.77
[D-Pen2,4'-125I-Phe4,D-Pen5]enkephalin: a selective high affinity radioligand for delta opioid receptors with exceptional specific activity. J Pharmacol Exp Ther (1991) 0.77
Metabolic half-life of somatostatin and peptidase activities are altered in Alzheimer's disease. J Gerontol (1992) 0.77
High-performance liquid-chromatographic separation and fluorescence measurement of biogenic amines in plasma, urine, and tissue. Clin Chem (1978) 0.77
Subchronic haloperidol administration decreases aminopeptidase N activity and [Met5]enkephalin metabolism in rat striatum and cortex. Eur J Pharmacol (1996) 0.77
Effect of milk on somatostatin degradation in suckling rat jejunum in vivo. J Pediatr Gastroenterol Nutr (1999) 0.77
beta-Endorphin and its metabolites stimulate motility of the dog small intestine. J Pharmacol Exp Ther (1983) 0.77
A specific enzyme assay for aminopeptidase M in rat brain. Life Sci (1992) 0.77
Ultrasound as used in thoracoabdominal trauma. Surg Clin North Am (1998) 0.77
Characterization of the peptide and sensory neurotoxic effects of capsaicin in the guinea pig. J Neurosci (1983) 0.76
Identification of beta-endorphin-6(16-17) as the principal metabolite of des-tyrosin-gamma-endorphin (DTgammaE) in vitro and assessment of its activity in neurotransmitter receptor binding assays. Eur J Pharmacol (1982) 0.76
Patients with epileptic seizures and cerebral lesions who underwent lesionectomy restricted to or associated with the adjacent irritative area. Epilepsia (1999) 0.76
The pro-enkephalin A derivative, peptide E, is centrally processed to active fragments. Proc West Pharmacol Soc (1984) 0.76
The proenkephalin A fragment, peptide E: central processing and CNS activity in vivo. Eur J Pharmacol (1985) 0.76